Shareholders back Theragenics' sale to Juniper; Cleveland Clinic picks 2014 innovators;

@FierceMedDev: Roche ekes out diagnostics growth as diabetes biz falters. More | Follow @FierceMedDev

@MarkHFierce: Another J&J hip lawsuit is settled. Will the company resolve the 11,000-plus suits that remain outstanding? Story | Follow @MarkHFierce

@MichaelGFierce: Trending from FierceDrugDelivery: Mini-pancreas grown from stem cells has implications for future  delivery. Article | Follow @MichaelGFierce

> Surgical devicemaker Theragenics' ($TGX) shareholders have approved a $68.3 million bid by private equity outfit Juniper to buy the company. Item

> OrthoSensor gained a CE mark for its system designed to aid surgeons during total knee replacement surgeries. Story

> Therapeutic hyperthermia doesn't increase the risk of stent thrombosis in patients who experience out-of-hospital cardiac arrest before a stent procedure. Story

> Futura Medical won a CE mark for a new erection-enhancing condom lined with a special gel. Story

> Enzo Biochem ($ENZ) will start selling a number of DiaSorin advanced diagnostic tools, with an option to expand its offerings in the future. Item   

> The Cleveland Clinic's pick for the top innovations of 2014 include a computer-assisted personalized sedation system and a bionic eye. Story

Biotech News

@FierceBiotech: Industry Voices: Clinical trial transparency--time for some carrot as well as more stick? Feature | Follow @FierceBiotech

@JohnCFierce: Danish biotech Egalet pitches $69M IPO on Nasdaq. News | Follow @JohnCFierce

@DamianFierce: Fresh off a staggering FDA rejection, Wright is spending $80M on an implant outfit. Story | Follow @DamianFierce

@EmilyMFierce: AstraZeneca, Harvard's Wyss Institute partner to advance 'Organs-on-Chips' drug-testing tech. Item | Follow @EmilyMFierce

> Aragon begets Seragon as VCs bankroll $30M cancer drug spinoff. Article

> Roche: Forget mega-mergers, focus on a new round of blockbuster bolt-ons. Story

> Amarin shares shrivel after FDA experts spurn Vascepa. Item

> AstraZeneca, Amgen Crohn's drug runs into PhII 'logistical' snafu. Report

Pharma News

@FiercePharma: Top news yesterday: Teva halts Israeli layoffs amid pressure from labor, gov't. Report | Follow @FiercePharma

@CarlyHFierce: Eisai to recruit 200 new sales reps for amped-up Belviq push. ICYMI yesterday | Follow @CarlyHFierce

> FDA experts vote against expansion of Amarin's Vascepa. News

> Pharma dealmakers, listen up: Ireland may close a popular tax loophole. Story

> Roche CEO scuttles Novartis merger talk. More

Pharma Manufacturing News

@EricPFierce: Another gut check for Amarin and its fish oil drug  panel votes against wider use. News | Follow @EricPFierce

> In turnabout, U.K. tells Wockhardt to recall 5 drugs. Report

> Federal case over drug shortage comes to an end. Story

> Teva reconsiders production cuts in Israel. Item

> B. Braun recalls product after organic particulate found. More

> Genzyme expanding U.S. plant opened last year. Article

Vaccines News

> Cost of rabies vaccine limiting use in Africa. Report

> Merck, Sanofi report on first vaccine in European pilot project. More

> IOM releases modeling software for vaccine prioritization. Item

> Novartis cuts jobs in California as eastward shift continues. More

> India to expand use of pentavalent vaccine after safety thumbs-up. Article

> U.K. court orders sisters to receive MMR vaccine. Story

Suggested Articles

The randomized, blinded study showed statistically significant improvements in assessments of inattention and brain activity.

U.K.-based surgery robot developer CMR Surgical has begun rolling out its Versius platform to the NHS, completing its first procedures in Europe.

The former Fierce 15 winner’s SuperMap program was cleared to guide electrophysiologists in the treatment of stable and transient arrhythmias.